VERACYTE INC (VCYT) Stock Fundamental Analysis
NASDAQ:VCYT - US92337F1075 - Common Stock
30.34 USD
+0.39 (+1.3%)
30.34 USD
0 (0%)
Overall VCYT gets a fundamental rating of 6 out of 10. We evaluated VCYT against 542 industry peers in the Biotechnology industry. VCYT has an excellent financial health rating, but there are some minor concerns on its profitability. VCYT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
VCYT had positive earnings in the past year.
In the past year VCYT had a positive cash flow from operations.
VCYT had negative earnings in 4 of the past 5 years.
In multiple years VCYT reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 1.96%, VCYT belongs to the best of the industry, outperforming 90.22% of the companies in the same industry.
VCYT has a Return On Equity of 2.16%. This is amongst the best in the industry. VCYT outperforms 90.96% of its industry peers.
VCYT has a Return On Invested Capital of 2.32%. This is amongst the best in the industry. VCYT outperforms 90.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.96% | ||
| ROE | 2.16% | ||
| ROIC | 2.32% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCYT has a Profit Margin of 5.50%. This is amongst the best in the industry. VCYT outperforms 91.14% of its industry peers.
VCYT has a better Operating Margin (7.78%) than 91.33% of its industry peers.
The Gross Margin of VCYT (68.26%) is better than 80.44% of its industry peers.
VCYT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.78% | ||
| PM (TTM) | 5.5% | ||
| GM | 68.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), VCYT is destroying value.
VCYT has more shares outstanding than it did 1 year ago.
VCYT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VCYT has an Altman-Z score of 11.93. This indicates that VCYT is financially healthy and has little risk of bankruptcy at the moment.
VCYT has a Altman-Z score of 11.93. This is amongst the best in the industry. VCYT outperforms 87.64% of its industry peers.
There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.93 |
ROIC/WACC0.24
WACC9.86%
2.3 Liquidity
VCYT has a Current Ratio of 5.43. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
VCYT has a Current ratio (5.43) which is in line with its industry peers.
A Quick Ratio of 5.10 indicates that VCYT has no problem at all paying its short term obligations.
With a Quick ratio value of 5.10, VCYT perfoms like the industry average, outperforming 57.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.43 | ||
| Quick Ratio | 5.1 |
3. Growth
3.1 Past
VCYT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 144.00%, which is quite impressive.
The Revenue has grown by 19.91% in the past year. This is quite good.
VCYT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.93% yearly.
EPS 1Y (TTM)144%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
Revenue 1Y (TTM)19.91%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.75%
3.2 Future
VCYT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.40% yearly.
VCYT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.94% yearly.
EPS Next Y24.95%
EPS Next 2Y67.99%
EPS Next 3Y64.53%
EPS Next 5Y51.4%
Revenue Next Year12.56%
Revenue Next 2Y11.11%
Revenue Next 3Y10.51%
Revenue Next 5Y9.94%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 91.94, the valuation of VCYT can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 90.41% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.13, VCYT is valued quite expensively.
Based on the Price/Forward Earnings ratio of 35.84, the valuation of VCYT can be described as expensive.
Based on the Price/Forward Earnings ratio, VCYT is valued cheaper than 90.41% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.76, VCYT is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.94 | ||
| Fwd PE | 35.84 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 91.70% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 93.91% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.43 | ||
| EV/EBITDA | 32.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of VCYT may justify a higher PE ratio.
VCYT's earnings are expected to grow with 64.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.68
PEG (5Y)N/A
EPS Next 2Y67.99%
EPS Next 3Y64.53%
5. Dividend
5.1 Amount
No dividends for VCYT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
30.34
+0.39 (+1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners107.53%
Inst Owner Change0.85%
Ins Owners0.6%
Ins Owner Change2.99%
Market Cap2.39B
Analysts83.33
Price Target42.05 (38.6%)
Short Float %11.66%
Short Ratio5.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.08%
Min EPS beat(2)-110.32%
Max EPS beat(2)72.17%
EPS beat(4)2
Avg EPS beat(4)123.1%
Min EPS beat(4)-110.32%
Max EPS beat(4)579.09%
EPS beat(8)4
Avg EPS beat(8)77.32%
EPS beat(12)8
Avg EPS beat(12)65.1%
EPS beat(16)11
Avg EPS beat(16)51.9%
Revenue beat(2)2
Avg Revenue beat(2)3.39%
Min Revenue beat(2)1.01%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.45%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.09%
Revenue beat(12)11
Avg Revenue beat(12)5.21%
Revenue beat(16)15
Avg Revenue beat(16)5.61%
PT rev (1m)-1.62%
PT rev (3m)-5.73%
EPS NQ rev (1m)-5.77%
EPS NQ rev (3m)-27.94%
EPS NY rev (1m)-27.7%
EPS NY rev (3m)-41.48%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)-0.33%
Revenue NY rev (1m)1.44%
Revenue NY rev (3m)1.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.94 | ||
| Fwd PE | 35.84 | ||
| P/S | 4.98 | ||
| P/FCF | 28.43 | ||
| P/OCF | 25.54 | ||
| P/B | 1.95 | ||
| P/tB | 6.78 | ||
| EV/EBITDA | 32.61 |
EPS(TTM)0.33
EY1.09%
EPS(NY)0.85
Fwd EY2.79%
FCF(TTM)1.07
FCFY3.52%
OCF(TTM)1.19
OCFY3.92%
SpS6.09
BVpS15.52
TBVpS4.47
PEG (NY)3.68
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.96% | ||
| ROE | 2.16% | ||
| ROCE | 2.94% | ||
| ROIC | 2.32% | ||
| ROICexc | 3.11% | ||
| ROICexgc | 37.8% | ||
| OM | 7.78% | ||
| PM (TTM) | 5.5% | ||
| GM | 68.26% | ||
| FCFM | 17.52% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score7
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 41.28% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 155.1% | ||
| Profit Quality | 318.84% | ||
| Current Ratio | 5.43 | ||
| Quick Ratio | 5.1 | ||
| Altman-Z | 11.93 |
F-Score7
WACC9.86%
ROIC/WACC0.24
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)144%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
EPS Next Y24.95%
EPS Next 2Y67.99%
EPS Next 3Y64.53%
EPS Next 5Y51.4%
Revenue 1Y (TTM)19.91%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.75%
Revenue Next Year12.56%
Revenue Next 2Y11.11%
Revenue Next 3Y10.51%
Revenue Next 5Y9.94%
EBIT growth 1Y52395.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year253.37%
EBIT Next 3Y67.47%
EBIT Next 5Y43.98%
FCF growth 1Y264.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y198.77%
OCF growth 3YN/A
OCF growth 5YN/A